We’re sharing an important update many of our patients have been asking about.

On September 25, 2025, the Lenire™ tinnitus treatment device received regulatory approval for sale in Canada. This milestone follows Neuromod Devices’ certification under the Medical Device Single Audit Program (MDSAP), which includes Health Canada and Australia’s Therapeutic Goods Administration (TGA).

What Does Approval Mean?

Health Canada’s approval confirms that Lenire™ meets national safety and quality standards for medical devices. It’s a positive step—but not a guarantee of effectiveness for every patient.

While recent studies, including a 2025 peer-reviewed real-world trial, show promise, the independent evidence base is still evolving. Results vary, and we don’t yet have enough high-quality data to confidently recommend Lenire™ across the broader tinnitus population.

Our Position at Salus Hearing and Tinnitus Centre

At Salus, your safety and outcomes come first. We’re closely monitoring new research, regulatory updates, and clinical experiences with Lenire™. If future evidence supports consistent, meaningful benefits—and if practical considerations like training, follow-up care, and patient support are in place—we’ll let you know whether we plan to offer Lenire™ in our clinics.

Have Questions?

We’re here to help. If you’d like to discuss current tinnitus care options or explore what might be right for you, call us at 289-963-1512 or request a call back. Our team is happy to guide you through science-based solutions tailored to your needs.